Figure 2.

Disposition of participants in the EXTEND study.

AE, adverse event; DAC, daclizumab; IFN, interferon; ITT, intention-to-treat. ^aOne participant assigned to the Continuous DAC beta group discontinued before receiving treatment in EXTEND.